ID: ALA3134464

Max Phase: Preclinical

Molecular Formula: C23H24ClN3O6S

Molecular Weight: 505.98

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOC(=O)C1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc(Cl)s4)OC3=O)cc2)C(=O)C1

Standard InChI:  InChI=1S/C23H24ClN3O6S/c1-2-32-22(30)14-9-10-26(20(28)11-14)15-3-5-16(6-4-15)27-13-17(33-23(27)31)12-25-21(29)18-7-8-19(24)34-18/h3-8,14,17H,2,9-13H2,1H3,(H,25,29)/t14?,17-/m0/s1

Standard InChI Key:  FBSPBKVAYDDUBU-JRZJBTRGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 505.98

Molecular Weight (Monoisotopic): 505.1074

AlogP: 3.46

#Rotatable Bonds: 7

Polar Surface Area: 105.25

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.60

CX Basic pKa:

CX LogP: 2.64

CX LogD: 2.64

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.58

Np Likeness Score: -1.53

References

1. Trstenjak U, Ilas J, Kikelj D.  (2014)  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety,  5  (2): [10.1039/C3MD00250K]

Source

Source(1):

• Scientific Literature